Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus

被引：0
作者：
Anca D. Askanase
George J. Wan
Mary P. Panaccio
Enxu Zhao
Julie Zhu
Roman Bilyk
Richard A. Furie
机构：
[1] Columbia University Irving Medical Center,
[2] Mallinckrodt Pharmaceuticals,undefined
[3] Zucker School of Medicine at Hofstra/Northwell,undefined
来源：
Rheumatology and Therapy | 2021年 / 8卷
关键词：
Acthar Gel; Autoimmune disease; Glucocorticoid; Patient-reported outcomes; Repository corticotropin injection; Systemic lupus erythematosus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：573 / 584
页数：11
相关论文
共 50 条
  • [41] The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial
    H. P. Bhattoa
    P. Bettembuk
    A. Balogh
    G. Szegedi
    E. Kiss
    Osteoporosis International, 2004, 15 : 396 - 404
  • [42] DESIGN OF A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIAL OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
    Werth, V. P.
    Merola, J. F.
    Wenzel, J.
    Delev, N.
    Kothari, H.
    Meier, R.
    Singhal, S.
    Madireddi, M.
    Korish, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1506 - 1506
  • [43] Comparisons and correlations of 1-month recall vs 24-hour recall in patient-reported outcomes of an exploratory, phase 2b, randomized, double-blind, placebo-controlled clinical trial of sildenafil cream, 3.6% for the treatment of female sexual arousal disorder
    Johnson, Isabella
    Thurman, Andrea Ries
    Cornell, Katherine A.
    Symonds, Tara
    Hatheway, Jessica
    Friend, David R.
    Goldstein, Andrew
    JOURNAL OF SEXUAL MEDICINE, 2024, 21 (09) : 787 - 792
  • [44] Correction of omega-3 fatty acid deficiency and improvement in disease activity in patients with systemic lupus erythematosus treated with krill oil concentrate: a multicentre, randomised, double-blind, placebo-controlled trial
    Salmon, Jane
    Wallace, Daniel J.
    Rus, Violeta
    Cox, Addison
    Dykas, Claire
    Williams, Brooke
    Ding, Yunpeng
    Hals, Petter-Arnt
    Johnsen, Line
    Lipsky, Peter E.
    LUPUS SCIENCE & MEDICINE, 2024, 11 (02):
  • [45] Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: A double-blind placebo-controlled trial
    Abdou, Nabih I.
    Rider, Virginia
    Greenwell, Cindy
    Li, Xiaolan
    Kimler, Bruce F.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (05) : 797 - 803
  • [46] Initial Results From Summit: An Ongoing, 3-Part, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients With Non-Advanced Systemic Mastocytosis (NonAdvSM)
    Bose, Prithviraj
    Rein, Lindsay A. M.
    Oh, Stephen T.
    DeAngelo, Daniel J.
    Hunter, Anthony M.
    Akin, Cem
    Castells, Mariana
    Manning, Michael
    Herrscher, Richard
    Ustun, Celalettin
    Kirshenbaum, Arnold
    Livideanu, Cristina Bulai
    Boggs, Nathan A.
    Yi, Cecilia Arana
    Siebenhaar, Frank
    George, Tracy I.
    Exter, Benjamin
    Zhang, Jenna
    Pilla, Amanda
    Jolin, Hina
    Easton, Rachael
    Modena, Brian D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S429 - S429
  • [47] Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)
    Simpson, Eric L.
    Gadkari, Abhijit
    Worm, Margitta
    Soong, Weily
    Blauvelt, Andrew
    Eckert, Laurent
    Wu, Richard
    Ardeleanu, Marius
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Sutherland, E. Rand
    Mastey, Vera
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (03) : 506 - 515
  • [48] Patient-Reported Outcomes in Women With Breast Cancer Enrolled in a Dual-Center, Double-Blind, Randomized Controlled Trial Assessing the Effect of Acupuncture in Reducing Aromatase Inhibitor-Induced Musculoskeletal Symptoms
    Bao, Ting
    Cai, Ling
    Snyder, Claire
    Betts, Kelly
    Tarpinian, Karineh
    Gould, Jeff
    Jeter, Stacie
    Medeiros, Michelle
    Chumsri, Saranya
    Bardia, Aditya
    Tan, Ming
    Singh, Harvinder
    Tkaczuk, Katherin H. R.
    Stearns, Vered
    CANCER, 2014, 120 (03) : 381 - 389
  • [49] Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus
    Bengtsson, Anders A.
    Sturfelt, Gunnar
    Lood, Christian
    Ronnblom, Lars
    van Vollenhoven, Ronald F.
    Axelsson, Bengt
    Sparre, Birgitta
    Tuvesson, Helen
    Ohman, Marie Wallen
    Leanderson, Tomas
    ARTHRITIS AND RHEUMATISM, 2012, 64 (05): : 1579 - 1588
  • [50] Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
    Padidela, Raja
    Whyte, Michael P.
    Glorieux, Francis H.
    Munns, Craig F.
    Ward, Leanne M.
    Nilsson, Ola
    Portale, Anthony A.
    Simmons, Jill H.
    Namba, Noriyuki
    Cheong, Hae Il
    Pitukcheewanont, Pisit
    Sochett, Etienne
    Hogler, Wolfgang
    Muroya, Koji
    Tanaka, Hiroyuki
    Gottesman, Gary S.
    Biggin, Andrew
    Perwad, Farzana
    Williams, Angela
    Nixon, Annabel
    Sun, Wei
    Chen, Angel
    Skrinar, Alison
    Imel, Erik A.
    CALCIFIED TISSUE INTERNATIONAL, 2021, 108 (05) : 622 - 633
12345